Alkermes (ALKS) to Release Quarterly Earnings on Tuesday

Alkermes (NASDAQ:ALKS) will likely be issuing its Q1 2026 results before the market opens on Tuesday, May 5th. Analysts expect Alkermes to post earnings of ($0.57) per share and revenue of $363.2910 million for the quarter. Investors can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:00 AM ET.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Saturday, February 14th. The company reported $0.29 EPS for the quarter. The firm had revenue of $384.55 million for the quarter. Alkermes had a net margin of 16.37% and a return on equity of 14.91%. On average, analysts expect Alkermes to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Alkermes Stock Performance

Shares of NASDAQ:ALKS opened at $33.58 on Monday. The company has a market capitalization of $5.58 billion, a P/E ratio of 23.47 and a beta of 0.31. The company’s 50-day moving average is $31.44 and its 200 day moving average is $30.95. Alkermes has a fifty-two week low of $25.17 and a fifty-two week high of $36.48.

Analyst Ratings Changes

ALKS has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Alkermes from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Truist Financial raised shares of Alkermes to a “strong-buy” rating in a report on Wednesday, March 25th. Piper Sandler lowered their price objective on shares of Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a research note on Tuesday, March 24th. HC Wainwright reiterated a “neutral” rating and set a $43.00 target price on shares of Alkermes in a report on Thursday, February 26th. Finally, Royal Bank Of Canada cut their target price on Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Alkermes has an average rating of “Moderate Buy” and a consensus price target of $44.29.

Insider Activity at Alkermes

In other Alkermes news, SVP Christian Todd Nichols sold 6,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $30.00, for a total value of $180,000.00. Following the transaction, the senior vice president owned 109,769 shares of the company’s stock, valued at approximately $3,293,070. This represents a 5.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Craig C. Hopkinson sold 9,000 shares of Alkermes stock in a transaction on Friday, May 1st. The shares were sold at an average price of $33.40, for a total value of $300,600.00. Following the transaction, the executive vice president owned 81,389 shares in the company, valued at $2,718,392.60. This trade represents a 9.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 37,068 shares of company stock valued at $1,197,561. 4.59% of the stock is owned by insiders.

Institutional Trading of Alkermes

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after buying an additional 1,256,377 shares in the last quarter. Arrowstreet Capital Limited Partnership grew its holdings in Alkermes by 1,070.6% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,208,944 shares of the company’s stock valued at $36,268,000 after purchasing an additional 1,105,666 shares during the last quarter. BNP Paribas Financial Markets raised its position in Alkermes by 787.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 1,135,478 shares of the company’s stock worth $32,486,000 after purchasing an additional 1,007,488 shares during the period. State Street Corp raised its position in Alkermes by 10.9% in the 4th quarter. State Street Corp now owns 9,472,858 shares of the company’s stock worth $265,051,000 after purchasing an additional 932,507 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in Alkermes by 19.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,412,783 shares of the company’s stock worth $123,467,000 after purchasing an additional 714,787 shares during the last quarter. Institutional investors own 95.21% of the company’s stock.

About Alkermes

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.